Skip to main content

A Non-Invasive Alternative To Intravenous Options For Stopping Status EPILEPTICUS

Most seizures do not last longer than 2 minutes. Sometimes, however, a seizure continues and may progress to become a seizure emergency. This may be referred to as status epilepticus (SE). SE is a medical emergency associated with significant morbidity and mortality. Over the past several decades, it has become known that damage to a seizing brain occurs earlier and the length of a seizure defined as SE has shortened. SE is currently defined as a continuous seizure lasting more than 5 minutes, or 2 or more seizures without full recovery of consciousness in between seizures.


SE is typically treated by medical professionals with intravenous (IV) medications. However, establishing intravenous access may take time and can be difficult to achieve in actively seizing patients. In such cases, an alternative route of administration may be necessary. The currently available alternatives to IV administration are limited.

About NRL-3

We are developing NRL-3, a proprietary nasal spray formulation of a benzodiazepine (other than diazepam) and Intravail®, for the acute treatment of status epilepticus (SE).* There are an estimated 152,000 SE cases per year in the United States, resulting in 42,000 deaths and an inpatient medical treatment cost of up to $7.0 billion per year. We believe NRL-3, if approved, has the potential to enable caregivers to treat patients experiencing SE and potentially cease their seizure activity. We expect to submit our IND and begin clinical trials in 2022.

*NRL-3 is an investigational product candidate that has not been approved by FDA for any indication.